Status:
COMPLETED
Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course
Lead Sponsor:
Weill Medical College of Cornell University
Collaborating Sponsors:
Genzyme, a Sanofi Company
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
Up to 89 years
Brief Summary
Chart review.
Detailed Description
A chart review will be completed on patients with multiple sclerosis to determine potential early characteristics that might be helpful in defining aggressive onset MS and predicting subsequent diseas...
Eligibility Criteria
Inclusion
- Two or more relapses in the preceding year and 2 or more gadolinium enhancing lesions on brain MRI scan or a significant T 2 lesion burden or
- One relapse if it results in sustained EDSS of 3.0 along with 2 or more gadolinium enhancing lesions or significant T2 lesion burden ( T2 lesion burden being determined by factoring the number of lesions, the size of the lesions and lesion location)
Exclusion
- \-
Key Trial Info
Start Date :
August 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT02301572
Start Date
August 1 2014
End Date
August 1 2016
Last Update
May 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medical College
New York, New York, United States, 10021